An update of the surgical indications for gastrointestinal stromal tumors;Actualisation des indications chirurgicales des tumeurs stromales gastrointestinales

Journal de Chirurgie

Volumn 145, Issue S3, 2008, Pages

  Bonvalot, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib; Sarcoma; Surgery

Indexed keywords

EID: 58149115201     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(08)74226-1     Document Type: Article

References (32)

1. Demetri GD, von Mehren M, Blanke CD, et al . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
2. DeMatteo R, et al . Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007, Abstract - No. 10079.
3. Blay JY, Landi B, Bonvalot S, et al. Recommandations pour le management des GIST. Bull Cancer 2005;92:907-918.
4. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-578.
5. De Matteo RP, Lewis JJ, Leug D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
6. Bonvalot S, Rouquié D, Vanel D, Domont J, Le Cesne A. Chirurgie des tumeurs stromales gastro-intestinales aux stades localisés et métastatiques. Oncologie 2007;9:102-106.
7. Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139:484-492.
8. Nguyen SQ, Divino CM, Wang JL, Dikman SH. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc 2006;20:713-716.
9. Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors Ann Surg 2006;243:738-745.
10. Aparicio T, Boige V, Sabourin JC, et al . Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004;30:1098-1103.
11. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
12. Miettinen M, El-Rifai W, H L Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-483.
13. Hassan I, You YN, Dozois EJ, et al. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 2006;49:609-615.
14. Changchien CR, Wu MC, Tasi WS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 2004;47:1922-1929.
15. Le Cesne A, Landi B, Bonvalot S, et al. Recommendations for the management of gastro-intestinal stromal tumors. Ann Pathol 2006;26:231-234.
16. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489.
17. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006;37:1527-1535.
18. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-120.
19. Park YS, Park SW, Kim TI, et al. Endoscopic enucleation of upper-GI submucosal tumors by using an insulated-tip electrosurgical knife. Gastrointest Endosc 2004;59:409-415.
20. Sun S, Ge N, Wang C, Wang M, Lü Q. Endoscopic band ligation of small gastric stromal tumors and follow-up by endoscopic ultrasonography. Surg Endosc 2007 ; 21 : 574-578.
21. Lee IL, Lin PY, Tung SY, Shen CH, Wei KL, Wu CS. Endoscopic submucosal dissection for the treatment of intraluminal gastric subepithelial tumors originating from the muscularis propria layer. Endoscopy 2006 ; 38 : 1024-1028.
22. Wehrmann T, Martchenko K, Nakamura M, Riphaus A, Stergiou N. Endoscopic resection of submucosal esophageal tumors: a prospective case series. Endoscopy 2004;36:802-807.
23. Gold JS, van der Zwan SM, Gönen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007;14:134-142.
24. Verweij J, Casali PG, Zalcberg J, et al . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
25. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13:1596-1603.
26. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341-346.
27. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
28. Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003;50:438-442.
29. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25:1107-1113.
30. Stoeckle E, Meeus P, Rios P, et al. Complete resection of residual disease in responding patients to imatinib (IM) positively influences the outcome of patients with advanced GIST: the experience of the BFR14 trial of the French Sarcoma Group. ASCO 2008. Abstract 10549.
31. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665-669.
32. Zalcberg JR, Verweij J, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-1757.